A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis (DR-TB) and provide access to effective cure and prevention of DR-TB throughout the world.

Over ten million people will develop tuberculosis (TB) in the world this year; over 500,000 of these will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and regimens involving new TB drugs in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter click here!


Developments in MDR-TB

FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs

Posted on 08/15/19

The FDA has approved a new drug for highly-resistant forms of drug-resistant tuberculosis. Developed by the non-profit TB alliance, Pretomanid has been approved to be used in a combination regimen with bedaquiline and linezolid for people with MDR-TB and XDR-TB.

Public call for individual patient data on treatment of drug-resistant TB

Posted on 08/07/19

The World Health Organization (WHO) is developing new guidelines for the treatment of drug-resistant TB (DR-TB) by issuing a public call appealing to industry, researchers, national TB programs, and other agencies to provide appropriate datasets.

For more news, click here.